Article

Epigenetic silencing of PTEN and epi-transcriptional silencing of MDM2 underlied resistance to hypomethylating agents in myelodysplastic syndrome

2022-04-19

Abstract excerpt

<h4>Background: </h4> In myelodysplastic syndrome (MDS), resistance to hypomethylating agents (HMA) portends a poor prognosis, underscoring the importance of understanding the molecular mechanisms leading to HMA-resistance. <h4>Methods: </h4> In this study, P39 and Kasumi-1 cells and their azacitidine-resistant and decitabine-resistant sublines were evaluated comparatively with transcriptomic and methylomic analys...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5cab0958-0b69-57d8-9976-79c0a7557bc2
DOI: 10.21203/rs.3.rs-1274380/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Epigenetic silencing of PTEN and epi-transcriptional silencing of MDM2 underlied resistance to hypomethylating agents in myelodysplastic syndromeDOI 10.21203/rs.3.rs-1274380/v2Read

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read

Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?Semantic proximity Read

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.Semantic proximity Read

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read

Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemiaSemantic proximity Read

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDSSemantic proximity Read

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related diseaseSemantic proximity Read

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.Semantic proximity Read